One study explored the differences in plasma metabonomics between MDD patients and healthy people, in which 52 identified metabolites showed differences between the two groups, including the levels of decenoylcarnitine (C10:1), decadienylcarnitine (C10:2), tetradecadienylcarnitine (C14:2), tetradecatrienecarnitine (C14:3), hexanoylcarnitine (C6:0), octanoylcarnitine (C8:0), decanoylcarnitine (C10:0), dodecanoylcarnitine (C12:0), and C3:0
This reveals that consumers are not leaving the restaurant scene
Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: therapeutic implications for cardiovascular diseases
However, potential side effects can include: Nausea or dizziness (rare) Headaches Injection site irritation Overstimulation or fatigue if overdosed There are no long-term human trials, so effects on hormones, organs, or chronic use remain unknown
M.MorklS.O'MahonyS